Theme · China plus one
Pharma and CDMO stocks theme: the China-plus-one supply-chain story
The pharma and CDMO theme groups Indian drug makers and contract development and manufacturing names riding a global push to diversify supply chains away from a single-country dependence.
The read
The pharma and CDMO theme groups Indian drug makers and contract development and manufacturing (CDMO) names riding a global push to diversify drug-supply chains away from single-country dependence, plus a steady domestic-formulations base; BazaarBaazi reads the theme at a Theme Heat of 84/100 as of 9 June 2026, a hot reading. It is editorial sentiment, not investment advice.
BazaarBaaziSource & method
What is driving the pharma and CDMO theme
The pharma theme has two engines. The defensive one is the domestic formulations and generics business, a steady grower tied to healthcare spend that does well regardless of the market mood. The more exciting one is CDMO, contract development and manufacturing, where Indian companies win outsourced work from global drug innovators looking to diversify their supply chains away from a single-country dependence.
That China-plus-one push is the structural tailwind. As global pharma de-risks its supply chain, Indian API makers and CDMO players with the right quality systems and capacity are natural beneficiaries. The bellwether names in custom synthesis and contract research are the cleanest expression of that shift.
How BazaarBaazi reads it
The desk values the defensiveness and the optionality together. The domestic-and-generics base gives the theme a floor that most cyclical themes lack, while the CDMO leg gives it the growth optionality. Conviction favours the names with proven regulatory track records and real CDMO order books over those riding the label alone.
The honest caveats are regulatory and cyclical. US inspections and generic-pricing pressure can hit earnings and sentiment hard, and CDMO order flow ebbs and flows with global innovator pipelines and biotech funding. This is a quality theme where the company's compliance record and customer book matter more than the sector narrative. Theme Heat reads the structural shift, not any single name's inspection risk.
The names
The listed names this theme spans, grouped by their role. This is an editorial grouping, not a buy list or a model portfolio.
Sun Pharma
The largest Indian drug maker, specialty plus generics.
Divi's Laboratories
API and custom-synthesis leader, a CDMO bellwether.
Laurus Labs
APIs and a growing CDMO and biologics franchise.
Syngene International
Contract research and manufacturing services.
What breaks the thesis
Every theme has a way it goes wrong. Read these before the story.
- US regulatory inspections and pricing pressure in generics hit earnings and sentiment.
- CDMO order flow depends on global innovator pipelines and funding cycles.
- Currency and input-cost swings affect export-heavy economics.
FAQ5 reader questions · AEO-eligible
Common questions on the pharma and cdmo theme.
What is the China-plus-one theme in pharma?
It is the global push by drug innovators to diversify their supply chains away from dependence on a single country. Indian API and CDMO companies with the right quality systems and capacity are natural beneficiaries of that shift.
What is a CDMO stock?
A CDMO (contract development and manufacturing organisation) makes drugs or intermediates for other pharma companies. Indian CDMO names win outsourced work from global innovators and are a key leg of the pharma supply-chain theme.
What is the risk in pharma stocks?
US regulatory inspections and generic-pricing pressure can hit earnings and sentiment, CDMO order flow depends on global innovator pipelines and funding, and currency and input-cost swings affect export-heavy economics.
Which are the main pharma and CDMO stocks?
Watched names include Sun Pharma, the largest Indian drug maker across specialty and generics, alongside Divi's Laboratories as an API and custom-synthesis CDMO bellwether, Laurus Labs in APIs and a growing CDMO and biologics franchise, and Syngene International in contract research and manufacturing services.
Are pharma stocks a long-term or short-term bet?
BazaarBaazi reads pharma as a quality theme with two engines: a defensive domestic-and-generics base that gives it a floor most cyclical themes lack, and a CDMO leg that supplies the growth optionality. Conviction favours names with proven regulatory track records and real CDMO order books over those riding the label alone.
Other themes
The other storylines the desk is tracking this year.
Hub
All themes
Rate cycle
Rate sensitives
The sectors that move on the RBI rate cycle, and how an easing bias helps each one.
Order books
Defence
PSU and private defence names riding indigenisation, export push, and multi-year order books.
Consumption shift
Quick commerce
The platforms and retailers reshaped by the rapid shift to 10-minute grocery and essentials delivery.
Re-rating
PSU banks
State-owned banks re-rating on cleaner books, better return ratios, and credit growth.